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The serodiagnosis of human tegumentary leishmaniasis (TL) presents some problems, such as the low level of antileishmanial
antibodies found in most of the patients, as well as the cross-reactivity in subjects infected by other trypanosomatids. In the
present study, an immunoproteomic approach was performed aimed at identification of antigens in total extracts of stationary-
phase promastigote and amastigote-like forms of Leishmania (Viannia) braziliensis using sera from TL patients. With the pur-
pose of reducing the cross-reactivity of the identified proteins, spots recognized by sera from TL patients, as well as those recog-
nized by antibodies present in sera from noninfected patients living in areas where TL is endemic and sera from Chagas disease
patients, were discarded. Two Leishmania hypothetical proteins and 18 proteins with known functions were identified as anti-
genic. The study was extended with some of them to validate the results of the immunoscreening. The coding regions of five of
the characterized antigens (enolase, tryparedoxin peroxidase, eukaryotic initiation factor 5a, -tubulin, and one of the hypothet-
ical proteins) were cloned in a prokaryotic expression vector, and the corresponding recombinant proteins were purified and
evaluated for the serodiagnosis of TL. The antigens presented sensitivity and specificity values ranging from 95.4 to 100% and
82.5 to 100%, respectively. As a comparative antigen, a preparation of Leishmania extract showed sensitivity and specificity val-
ues of 65.1 and 57.5%, respectively. The present study has enabled the identification of proteins able to be employed for the sero-
diagnosis of TL.
Leishmaniasis consists of a spectrum of diseases caused by pro-tozoan parasites of the genus Leishmania, which present high
morbidity and mortality throughout the world (1). Approxi-
mately 350million people in 98 countries are at risk of contracting
the infection, while nearly 1.0 to 1.5 million cases of tegumentary
leishmaniasis (TL) and 0.2 to 0.5 million cases of visceral leish-
maniasis (VL) are registered annually (2). Although TL is not a
fatal disease, it is endemic in more than 70 countries, and 90% of
the cases have occurred in Afghanistan, Algeria, Brazil, Pakistan,
Peru, Saudi Arabia, and Syria (3). The disease exhibits distinct
clinical manifestations, such as cutaneous leishmaniasis (CL), dif-
fuse cutaneous leishmaniasis (DCL), and mucosal leishmaniasis
(ML) (4, 5). In Brazil, TL is caused mainly by infection with the
species Leishmania (Viannia) braziliensis, Leishmania (V.) guya-
nensis, and Leishmania (Leishmania) amazonensis, although para-
sitological andmolecular evidence has shown that L. braziliensis is
the most important etiological agent of the disease (6, 7).
At present, there is no gold standard test for TL diagnosis, and
a combination of diagnostic methods is frequently needed to ob-
tainmore precise results (8). Parasitological diagnosis is definitive
and consists of the microscopic examination of Giemsa-stained
biopsy specimen smears, of histopathological examination or im-
munohistochemical approaches in lesion fragment triturates, and
by parasite in vitro cultures, as well as PCR. However, these tests’
sensitivity varies according to when the lesions occurred, and a
low number of parasites can be present in the late lesions, ham-
pering the sensitivity of the tests (8–13). Additionally, these tests
require invasive procedures of sample collection, which limit
their use.
The Montenegro skin test (MST) has been employed for the
immunological diagnosis of TL, although it does not make it pos-
sible to distinguish if the patients present either the acute or
chronic disease or if they have already been cured or are nonin-
fected subjects living in areas where the disease is endemic (14). In
this context, tests based on antileishmanial serology could be used
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to contribute to the laboratory diagnosis of the disease (15). How-
ever, the antigens usually employed can indicate false-positive re-
sults in serum samples fromnoninfected subjects living in areas of
endemicity where leishmaniasis is commonly found or in those
infected by other trypanosomatids, such as Trypanosoma cruzi.
On the other hand, these preparations can also indicate false-neg-
ative results for patients presenting low titers of antileishmanial
serology (8, 13, 16–20).
It is believed that the serum concentration of antileishmanial
antibodies can be directly related to the parasite load and to the
time of exposure to Leishmania antigens (21–23). Although the
role of antibodies in TL is not completely understood, evidence
has shown that the humoral response determined by specific IgG
reactivity to Leishmania antigens could well be used as an indica-
tor of the development of the disease, since some authors have
positively correlated the clinical cure of disease with a decrease in
the antileishmanial antibody titers, as well as to assist the clinical
follow-up during and after healing by the treatment of the patients
(23–27).
In this context, the search for more refined antigens of Leish-
mania spp. is necessary to identify molecules able to improve the
sensitivity and specificity values for the serodiagnosis of TL. In
addition, the identification of proteins able to predict the success
of a given treatment will help the follow-up of patients after treat-
ment. Only a few reports that applied proteomic methods for the
identification of L. braziliensis-excreted proteins or those related
to the development of different clinical forms of TL have been
published so far (28, 29). In this context, the present study applied
for the first time an immunoproteomic approach to the station-
ary-phase promastigote and amastigote-like stages of L. brazilien-
sis using sera from TL patients. The objective was the identifica-
tion of the most antigenic proteins to be applied for the
improvement of serodiagnosis of TL.With the purpose of refining
the selection of the candidate antigens, sera fromnoninfected sub-
jects living in regions of TL endemicity, as well as sera fromChagas
disease (CD) patients, were also used in the immunoblots to ex-
clude the cross-reactive proteins.
MATERIALS AND METHODS
Ethics statement. This study was conducted according to the Declaration
of Helsinki principles, and it was approved by the Ethics Committee from
Federal University of Minas Gerais (protocol no. CAAE–323431
14.9.0000.5149), Belo Horizonte, Minas Gerais, Brazil. All patients re-
ceived an individual copy of the study policy, which was reviewed by an
independent person, and all participants gave their consent form in Por-
tuguese before the collection of their blood sample.
Parasite. Leishmania (Viannia) braziliensis strain MHOM/BR/1975/
M2904 was used. Parasites were used until the 5th in vitro culture passage.
The promastigotes were grown at 24°C in Schneider’smedium (Sigma, St.
Louis, MO), which was supplemented with 10% inactivated fetal bovine
serum (FBS) (Sigma), 20 mM L-glutamine, 100 U/ml penicillin, and 100
g/ml streptomycin (pH 7.4) after reaching the stationary phase of the
culture. The soluble Leishmania antigenic extract (SLA) was prepared as
described previously (30). For the preparation of the amastigote-like
forms of L. braziliensis, 1 109 stationary promastigotes were washed in 5
ml of sterile phosphate-buffered saline (PBS). The parasites then were
incubated in 5ml of FBS for 48 h at 37°C. After that, parasites werewashed
two times in sterile PBS and visualized in an optical lightmicroscopy (31).
The cellular density was estimated by counting in a Neubauer chamber.
Also, the amastigote-like forms were used in in vitro experiments to infect
macrophages as a functional viability parameter.
Preparationof total extracts to 2DEgels.The total extracts of station-
ary-phase promastigotes and amastigotes-like forms of L. braziliensis, as
well as two-dimensional electrophoresis (2DE), were performed follow-
ing amodified technical protocol (32). Briefly, parasites in each stage (1
108) were resuspended in a DeStreak rehydration solution (GE Health-
care, Uppsala, Sweden) containing a protease inhibitor cocktail (GE
Healthcare) plus 1 mM phenylmethylsulfonyl fluoride (PMSF) (Sigma-
Aldrich). After homogenization, samples were disrupted by sonication in
ice bath for 15 min by applying a continuous pulse (with pulses of 30 s,
with a 15-s interval between them, at 38 MHz) and centrifuged at
20,000  g for 7 min at 4°C. The supernatant was collected, and the
protein concentration was estimated by the Bradford method (33).
IEF and SDS-PAGE. For the first-dimension electrophoresis, 150 g
of total extracts of the stationary promastigote and amastigote-like organ-
isms were resuspended in a volume of 125 l of rehydration solution
containing a DeStreak rehydration solution in 1% immobilized pH gra-
dient (IPG) buffer at pH4 to 7.Next, samples were applied to IPG strips (7
cm, pH 4 to 7 [GE Healthcare]) for passive rehydration for 18 h at room
temperature. After gel rehydration for 18 h, isoelectric focusing (IEF) was
performed using the Ettan IPGphor3 system at 1,000 V for 300 V/h, 5,000
V for 4,800V/h, and holding at 5,000 V for 3,000 V/h. After IEF, each strip
was incubated for 15 min in a solution composed of 50 mM Tris-HCl
buffer (pH 8.8), 6 M urea, 30% (vol/vol) glycerol, 2% (wt/vol) SDS,
0.002% bromophenol blue, and 1% (wt/vol) dithiothreitol (DTT), fol-
lowed by a second incubation step in the same buffer solution, excluding
DTT, which was replaced by 125 mM iodoacetamide. IPG strips were
transferred to 12% polyacrylamide and sealed with agarose solution (aga-
rose and bromophenol blue in a Tris-glycine cathode buffer). A protein
standard was used (Invitrogen BenchMark protein ladder). Electropho-
resis was performed in aMini-Protean II system (Bio-Rad) connected to a
MultiTemp II cooling bath (Amersham Biosciences), in a Tris-glycine-
SDS buffer. Proteins were separated at 30 mA/gel until the dye front had
reached the bottom of the 2DE gel.
Human sera.Blood samples from patients with a confirmed diagnosis
of TL (n 43), representing those developing either CL (n 23; includ-
ing 17 males and 6 females, with ages ranging from 30 to 65 years) or ML
(n 20; including 15males and 5 females, with ages ranging from25 to 60
years), all of them living in an area of leishmaniasis endemicity (Belo
Horizonte, Minas Gerais, Brazil), were used in this study. Diagnosis of TL
was confirmed when, in addition to clinical evaluation of lesions compat-
ible with either CL or ML, parasites were observed in Giemsa-stained
smears of biopsy specimens of skin (CL) and/ormucosal (ML) fragments.
As well, all patients presented positive results for the Montenegro skin
test. For this, the Leishmania antigen used was obtained from the L. ama-
zonensis IFLA/BR/1967/PH-8 strain containing 40mg of protein nitrogen
per ml, with 0.005 g per ml of phenol, which was provided by CPPI (In-
stituto de Saúde do Paraná, Centro de Produção e Pesquisa de Imunobi-
ológicos, Curitiba, Paraná, Brazil). The magnitude of the skin response
was assessed 48 to 72 h after intradermal injection of 0.1 ml of the antigen
into the anterior right forearm. The diameter of the induration was mea-
sured inmillimeters by outlining the indurated border, withMST consid-
ered positive if it measured5mm (34). In addition, two biopsy samples
collected from each patient were submitted to a conventional PCR tech-
nique, and they presented positive results for L. braziliensisDNA.None of
the TL patients had been previously treated with antileishmanial drugs
before the sample collection. All patients in this studywere integrated into
the clinical assistance program of the Clinical Hospital from UFMG and
received continuous medical assistance. Concomitantly, blood samples
were taken from a control group consisting of noninfected individuals
(n 30, including 10 males and 20 females, with ages ranging from 17 to
30 years). Subjects were selected from healthy people living in area of
disease endemicity (Belo Horizonte, Minas Gerais, Brazil). These subjects
were also clinically evaluated through anamnesis and physical examina-
tion, and they did not present any clinical signs or suspicion of leishman-
iasis. To exclude the cross-reactive spots in the immunoblot assays, blood
Duarte et al.
1188 cvi.asm.org November 2015 Volume 22 Number 11Clinical and Vaccine Immunology
samples from Chagas disease (CD) patients (n  10, including 7 males
and 3 females, with ages ranging from 24 to 58 years) were also collected
and employed. Infection was confirmed by hemoculture or by both the
Chagatest recombinant enzyme-linked immunosorbent assay (ELISA)
v.3.0 kit (Wiener Lab, Argentina) and the Chagatest hemagglutination
inhibition (HAI) assay (Wiener Lab). All blood samples were collected by
venipuncture of the medial vein in tubes without anticoagulant and were
kept at 37°C for 15 min, when they were centrifuged at 3,000  g for 15
min, and serum samples were separated and kept at80°C until use.
Cloning, expression, and purification of the recombinant proteins.
The gene regions codifying the enolase (LbrM.14.1330), tryparedoxin
peroxidase (LbrM.15.1100), hypothetical protein (LbrM.30.3350),
eukaryotic initiation factor 5a (LbrM.25.0580), and -tubulin
(LbrM.33.0920) were obtained and cloned in an expression vector.
Afterward, the recombinant proteins were expressed and purified to be
evaluated in ELISAs. For this, the L. braziliensis genomic DNA was used
to amplify the specific sequences using the following primers: for enolase,
forward primer 5=GCTAGCATGCCGATCCAGAAGGTGTA and reverse
primer 5=AAGCTTTTACGCCCAGCCGGAGTA; for tryparedoxin per-
oxidase, forward primer 5=GCTAGCATGTCCTGCGGTGACGCC and
reverse primer 5=AAGCTTTTACGCCCAGCCGGAGTA; for the hypo-
thetical protein, forward primer 5=GCTAGCATGATGTACACGGGCGAA
and reverse primer 5=AAGCTTCTAGTAGTCAGAATTGCTGA; for -tu-
bulin, forward primer GCTAGCATGCGTGAGATCGTTTCCTG and re-
verse primer 5=GAGCTCCTAGTAGGCCTCCTCCTC; and for eukaryotic
initiation factor 5a, forward primer 5=GCTAGCATGTCTGACGAGGA
CCACand reverse primer 5=AAGCTTCTACTTCTCCGCGGCATT.The re-
striction sites for the NheI (GCTAGC), HindIII (AAGCTT), and SacI (GAG
CTC) restriction enzymes are underlined in the sequences. The sequences
were added to the oligonucleotides for cloning purposes. The PCR-amplified
products were analyzed on agarose gels. They were excised from the gels,
purified, digested with the respective restriction enzymes, and ligated to a
similarly digested pET28a-TEV vector. The recombinant plasmids were in-
troduced to electrocompetent Escherichia coli BL21 Arctic Express (DE3)
cells (Agilent Technologies) by electroporation using a MicroPulser elec-
troporation apparatus (Bio-Rad Laboratories). The correct sequences’ in-
sertion was confirmed by their sequencing using the T7 primer (Macro-
gen, South Korea). The recombinant proteins were expressed by adding
1.0 mM IPTG (isopropyl--D-thiogalactopyranoside) (Promega, Can-
ada) for 24 h at 12°C with shaking at 200 g per min. Then the cells were
lysed by sonication (applying continuous pulses of 30 s, with 15-s intervals
between them, at 38 MHz) and centrifuged at 13,000  g for 20 min at
4°C. The recombinant proteins were purified under nondenaturing con-
ditions, using 5 ml His-Trap columns (GE Healthcare Life Science) at-
tached to a fast protein liquid chromatography (FPLC) system (GE
Healthcare Life Science). After purification, the recombinant proteins
were passed through a polymyxin-agarose column (Sigma) to remove
residual endotoxin content. Also, to verify their purity, the purified prod-
ucts were submitted to 10% SDS-PAGE.
ELISA for the serodiagnosis of TL. Previous titration curves were
performed to determine the most appropriate antigen concentration and
antibody dilution to be used. In order to evaluate the diagnostic perfor-
mance of the selected proteins for the TL serodiagnosis, the enolase,
tryparedoxin peroxidase, hypothetical protein, eukaryotic initiation fac-
tor 5a, and-tubulin proteins (employed at concentrations of 1.0, 0.5, 0.5,
0.05, and 0.01 g per well, respectively) were employed as antigens. L.
braziliensis SLA (2.0 g per well) was used as a comparative antigen. For
the assays, Falcon flexible microtiter immunoassay plates (Becton Dick-
inson) were coated with the antigens diluted in 100 l of coating buffer
(50 mM carbonate buffer) at pH 9.6 for 18 h at 4°C. Afterward, free
binding sites were blocked using 200l of PBS-T (PBS plus 0.05% Tween
20 at pH 7.0) containing 5% casein for 1 h at 37°C. After the plates had
been washed five times with PBS-T, they were incubated with 100 l of
individual sera (diluted 1:100 in PBS-T containing 0.5% casein), for 1 h at
37°C. The plates were washed five times using PBS-T and incubated with
a 1:10,000 dilution of horseradish peroxidase-conjugated anti-human
IgG antibody (catalog no. SAB3701282; Sigma-Aldrich) for 1 h at 37°C.
After the plates had beenwashed seven times with PBS-T, the reactionwas
developed by adding 100 l of a solution composed of 2 mg ortho-phen-
ylenediamine, 2l H2O2 (30 vol), and 10ml citrate-phosphate buffer (pH
5.0) for 30min and in the dark. The reactionwas stopped by adding 100l
of a solution composed of 25l 2 NH2SO4, and the optical density at 492
nm (OD492) was read in an ELISA microplate spectrophotometer (Mo-
lecular Devices, Spectra Max Plus, Canada). The ELISAs were performed
twice, and the data shown in this study are representative of one of them.
In addition, each serum sample was evaluated in triplicate, and positive
and negative controls were used in each plate in the different experiments.
2DE immunoblot assays and protein identification. The immuno-
blots were performed to select the protein spots that were recognized only
by antibodies in sera from CL and/or ML patients, excluding those also
reactive with sera from Chagas disease patients or from noninfected sub-
jects. For this, total extracts of stationary promastigotes and amastigote-
like parasites were separated electrophoretically and transferred onto ni-
trocellulose membranes (Schleicher & Schull, Dassel, Germany) by
semidry blotting for 2 h at 400 mA. Membranes were blocked in 5%
(wt/vol) low-fat dried milk and diluted in 10 ml of PBS-T for 2 h and at
room temperature. Next, membranes were washed 5 times (10 min each)
with PBS-T and incubated with the individual pools of sera. For this,
serum samples from CL (n 23) or ML (n 20) patients, as well as sera
from noninfected subjects (n 30) and those with Chagas= disease (n
10), were pooled in equal volumes, diluted in PBS-T (1:100 dilution), and
individually incubated with the membranes for 2 h at room temperature.
After this, the blots were washed 5 times with PBS-T and incubated with a
peroxidase-conjugated goat anti-human IgG secondary antibody (1:5,000
diluted in PBS-T) (catalog no. SAB3701282; Sigma-Aldrich) for 2 h at
room temperature. After being washed 5 times with PBS-T, immunoblots
were revealed with the ECL enhanced chemiluminescence Western blot-
ting detection reagent and ImageQuant LAS4000 device (GEHealthcare).
Equivalent gels were stained with colloidal Coomassie brilliant blue
G-250, following a technical procedure (35). For image analysis, the
stained gelswere scannedusing an ImageScanner III (GEHealthcare), and
the gel spots equivalent to those recognized only by antibodies of CL
and/or ML patients in the blots were excised manually for protein identi-
fication. Three independent preparations, each obtained from separate
parasite cultures, were used. One representative assay is shown in this
study.
Protein digestion, peptide extraction, and spot handling. Selected
spots were manually excised, and fragments were destained with a solu-
tion containing 50% methanol and 2.5% acetic acid. The proteins were
reduced in 10 mM DTT and alkylated with 50 mM iodoacetamide solu-
tion. After drying, gel fragments were placed on ice in a 50-l protease
solution (20 ng ml1 of a sequence-grade-modified trypsin in 25 mM
ammonium bicarbonate [Promega]) for 30min. Excess protease solution
was removed and replaced by 25 mM ammonium bicarbonate. Digestion
was performed for 18 h at 37°C. Peptide extraction was performed twice
for 15 min, using 30 l of a 50% acetonitrile–5% formic acid solution.
Trypsin (Promega) digests were concentrated in a speed vacuum (Savant)
and submitted to liquid chromatography-tandem mass spectrometry
(LC-MS/MS) analyses on an ion trap time of flight (IT-TOF) instrument.
The analyses were performed using an electrospray ion-trap time of flight
(ESI-IT-TOF) mass spectrometer (Shimadzu Co., Japan) coupled to a
binary ultrafast liquid chromatography (UFLC) system (20A Promi-
nence; ShimadzuCo., Japan). Aliquots were loaded using the autosampler
in a Discovery C18 column (2.2 m; 100.0 by 3.0 mm) and diluted in the
following binary solvent system: solvent A, water-formic acid at 999:1
(vol/vol); solvent B, acetonitrile (ACN)-water-formic acid (FA) (900:99:1
vol/vol/vol). The column was eluted at a constant flow rate of 0.2 ml/min
with a 5 to 60% gradient of solvent B for 40 min. The eluates were moni-
tored using a Shimadzu SPD-M20A PDA detector. Before introduction
into the mass spectrometer, the spray voltage was kept at 4.5 kV and the
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capillary voltage at 1.76 kV at 200°C. TheMS spectra were acquired under
positive mode and collected in the m/z range of 80 to 1,850. The MS/MS
spectra were acquired according to data-dependent acquisition (DDA)
parameters. Instrument control, data acquisition, Mascot generic format
(MGF) generation, and data processing were performed using our own
solutions (LCMS solution 3.60.361 version; Shimadzu).
Protein identification and database search. TheMGF files generated
by Protein Post Run Analyses software (Shimadzu Co., Japan) were ana-
lyzed using either theMascot Server v.2.4 or the Peaks Studio v.7 against a
customized database consisting of all UniProt entries of the genus Leish-
mania (downloaded on 31 July 2014). For this, the following parameters
were used: one missed cleavage, mass tolerance of 0.2 Da, fixed modifica-
tion with carbamidomethylcysteine, and variable modification with oxi-
dized methionine. The results are presented using the InChorus Peaks
Studio analysis, which combined the results from both the Mascot and
Peaks programs.
Data analysis. The statistical analyses were performed using Graph-
Pad Prism (version 5.0 forWindows),WinEpiscope (version 2.0 forWin-
dows), and Microsoft Excel (version 10.0). The cutoff was chosen based
on the point that provides the maximum values of sensitivity and speci-
ficity. The accuracy (AC) was analyzed according to the area under the
curve (AUC) relative to the receiver operating characteristic (ROC)
curves, considering a 95% confidence interval (95%CI). The ROC curves
were plottedwith the values from serum samples frompatients withCL or
MLversus those from the control group (noninfected subjects), according
to a sick/nonsick rating method. Fisher’s test was used to compare the
diagnostic performance among the evaluated antigens. P values of0.05
were considered statistically significant.
RESULTS
Immunoblot assays and identification of target proteins in sta-
tionary promastigote and amastigote-like forms of Leishmania
braziliensis. To evaluate the antigenicity of the spots resolved in
the 2DE gels of both parasite stages, immunoblotswere performed
using the different pools of the sera from the patients. Using blots
prepared from 2DE gels of promastigote-stage total protein ex-
tracts (equivalent to that shown in Fig. 1A), it was possible to
verify that about 158 spots were recognized by antibodies present
in the sera from ML patients (Fig. 1B). With the sera from CL
patients, about 147 spots were recognized in the immunoblots
(Fig. 1C). Serum samples from noninfected subjects and from
Chagas disease patients were also employed in the assays, and the
results showed that 31 and 122 spots, respectively, were identified
in the promastigote stage (Fig. 1D and E, respectively). Evaluating
the reactive patterns from 2DE blots prepared from gels obtained
in the amastigote-like stage of the parasites (a representative
FIG1 Two-dimensional profile and immunoproteomic analysis using the stationary-phase promastigote total extracts of Leishmania (Viannia) braziliensis. 2DE
was performed using total protein extracts (150 g) of stationary-phase promastigote-stage parasites (first dimension, IEF, pH range 4 to 7; second dimension,
12% SDS-PAGE). A stained gel is shown in panel A. Blots obtained from equivalent gels were revealed after incubation with pools of sera from mucosal (B) or
cutaneous (C) leishmaniasis patients, as well as with pools of sera from noninfected subjects (D) or from patients developing Chagas disease (E). Bound
antibodies were detected with conjugated goat anti-human IgG antibody at a 1:5,000 dilution. The x axis represents the tentative isoelectric point (pI), while the
y axis represents the approximate molecular mass (kDa), as determined by a commercial gel marker (BenchMark protein ladder). The 46 spots identified after
their specific recognition by antibodies in sera from TL patients are marked in the 2DE-stained gel shown in panel A.
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stained gel is shown in Fig. 2A), it was possible to verify that about
251 spots were recognized by antibodies of sera fromML patients
(Fig. 2B), whereas 197 spots were recognized by sera from CL
patients (Fig. 2C). Using the sera from noninfected subjects and
those from Chagas disease patients, about 20 and 133 spots, re-
spectively, were recognized in this parasite stage (Fig. 2D and E,
respectively). Excluding the cross-reactive spots, a total of 46 and
39 proteins were selected to be identified by mass spectrometry in
the promastigote and amastigote-like stages. The 2DE spots pro-
files obtained were reproducible in terms of the total number of
revealed protein spots, and their relative positions and intensities
in three independent preparations were determined. After mass
spectrometry, 20 proteins were finally identified. A summary of
the results is included in Table 1. Briefly, from the 20 identified
proteins, 2 hypothetical proteins and 18 proteins with known
functions were identified. Six proteins were expressed in the pro-
mastigote stage, 4 were found in the amastigote-like stage, and 10
were identified in both parasite stages. Also, 5 proteins were rec-
ognized only by sera fromML patients, whereas 15 proteins were
recognized by both serum sources. Between them, housekeeping
proteins, such as - and -tubulins, chaperonins, such as heat
shock proteins, and proteins related to parasite virulence, such as
enolase (36), actin (37), and paraflagellar rod protein 1D (38),
were identified. Proteins evaluated as diagnostic markers, such as
heat shock protein 83 (39) and -tubulin (40), as well as vaccine
candidates, such as the paraflagellar rod protein 1D (38) and heat
shock protein 70 (41), were also found.
Evaluation of some of the identified candidates expressed as
recombinant proteins for the serodiagnosis of TL. The regions
encoding five of the characterized proteins were cloned in a pro-
karyotic expression vector. These antigens were identified in the
immunoblots as protein spots in the promastigote stage (with spot
no. 1, 44, 11, and 9 for enolase, hypothetical protein, eukaryotic
initiation factor 5a, and -tubulin, respectively) and amastigote
stage (with spot no. 18, 37, 25, 39, and 28 for enolase, tryparedoxin
peroxidase, hypothetical protein, eukaryotic initiation factor 5a,
and -tubulin, respectively) of the parasites, and the correspond-
ing recombinant proteinswere expressed in bacteria, purified, and
employed as antigens to coat ELISA plates in order to validate
their use for the TL serodiagnosis. An SLA total extract prepared
from L. braziliensis promastigotes was used as a control and com-
parative antigen in the ELISAs. Serum samples from noninfected
control patients and from CL and MCL patients, as well as sera
from Chagas disease patients, were employed. The individual op-
FIG 2 Two-dimensional profile and immunoproteomic analysis using amastigote-like total extracts of Leishmania (Viannia) braziliensis. 2DE was performed
with total protein extracts (150 g) of amastigote-like parasite forms (first dimension, IEF, pH range 4 to 7; second dimension, 12% SDS-PAGE). A stained gel
is shown in panel A. Blots prepared from equivalent gels were revealed after incubation with pools of sera from mucosal (B) or cutaneous (C) leishmaniasis
patients, as well as with pools of sera from noninfected subjects (D) or from patients developing Chagas disease (E). Bound antibodies were detected with
conjugated goat anti-human IgG antibody at a 1:5,000 dilution. The x axis represents the tentative isoelectric point (pI), while the y axis represents the
approximate molecular mass (kDa), as determined by a commercial 2DE gel marker (BenchMark protein ladder). The 39 spots identified after their specific
recognition by antibodies in sera of TL patients are marked in a 2DE-stained gel shown in panel A.
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tical density (OD) values obtained against the different antigens
are shown in Fig. 3A, whereas ROC curves showing the diagnostic
value of each antigen are shown in Fig. 3B. The selected proteins,
namely, enolase, tryparedoxin peroxidase, hypothetical protein,
eukaryotic initiation factor 5a, and -tubulin, were recognized by
both serum sources (CL andML patients). Of note, cross-reactiv-
ity observed between SLA and sera from T. cruzi-infected patients
was absent when the individual antigens were employed. Regard-
ing the individual validation of each recombinant antigen (sum-
marized in Table 2), the tryparedoxin peroxidase presented the
best results for the serodiagnosis of both CL and ML conditions,
since its sensitivity and specificity valueswere 100% for both cases.
As indicated above, this antigen was able to distinguish all of the
Chagas disease patients and noninfected subjects from the CL and
ML patients. When the other recombinant proteins were evalu-
ated, eukaryotic initiation factor 5a showed sensitivity and speci-
ficity values of 100% and 92.5%, respectively. Enolase, -tubulin,
and the hypothetical protein presented sensitivity values of 100,
100, and 95.4%, respectively, whereas their specificity values were
85.0, 82.5, and 85.0%, respectively. The hypothetical protein was
able to recognize all sera from patients developingML, presenting
higher OD values than the other diagnostic antigens. As a conclu-
sion, all of them present better diagnostic properties than the SLA
(sensitivity and specificity values of 65.1% and 57.5%, respec-
tively) for the serodiagnosis of TL.
DISCUSSION
In the present study, an immunoproteomic approach was applied
to screen antigenic L. braziliensis proteins. The purpose was to
characterize individual parasite antigens able to be employed for
the serodiagnosis of human TL. For this, total extracts from sta-
tionary-phase promastigotes and amastigote-like parasites of L.
braziliensis resolved in 2DE gels were blotted and tested against
serum samples derived from CL and ML patients. For a more
refined selection in the identification of the reactive spots, blots
were also assayed against pools of sera from noninfected subjects
living in areas of disease endemicity, as well as against sera from
Chagas disease patients, in order to eliminate cross-reactive can-
didates.
Nowadays, the diagnosis of TL is based on clinical criteria as-
sociated with the laboratory diagnosis (8); however, problems re-
lated to the sensitivity of the tests have been described, since a
significant percentage of patients are classified as false negative in
the serological assays employing antigenic Leishmania prepara-
tions, due to the low levels of antileishmanial antibodies encoun-
tered in their serum samples (23). In relation to specificity, an
important problem for the TL serodiagnosis resides in the cross-
reactivity of the antigens with sera from noninfected subjects liv-
ing in areas of disease endemicity, as well as with serum samples
from patients developing related pathologies, such as Chagas dis-
ease, which can present cross-reactivity in the serological analysis
performed (42). Therefore, there is a necessity to identify new
antigens with higher sensitivity and specificity values than total
extracts to be used for the improvement in the serodiagnosis of
TL. The present study presents promising results, since differentL.
braziliensis proteins (including two hypothetical ones) were iden-
tified as antigenic by their recognition by antibodies of TL patients
but not by sera from noninfected subjects or Chagas disease pa-
tients.
Proteomic studies have been previously performedwith L. bra-
ziliensis with the purpose to identify excreted factors, as well as
proteins showing variations of expression in different L. brazilien-
sis strains producing diverse clinical forms of the disease (28, 29).
The present study is complementary to those performed, since
TABLE 1 Proteins identified in the total extracts from stationary-phase promastigote and amastigote-like stages from Leishmania braziliensis
Protein namea NCBI accession no.
Predicted mol




Promastigote Amastigote-like CL ML
Enolase XP_001563419.1 46.1 5.77 P P 	 	
Actin XP_001561807.1 21.0 5.11 P P 	 	
Heat shock protein 83 kDa XP_001567803.1 41.4 4.66 P A 	 	
-Tubulin CAM45582 49.7 4.65 P P 	 	
-Tubulin XP_001567862.1 49.8 4.45 P P 	 	
Eukaryotic initiation factor 5a XP_001565563.1 17.8 4.62 P P 	 	
Calpain-like cysteine peptidase XP_001563372.1 13,1 4.4 P P  	
14-3-3 protein-like protein XP_001568962.1 29.7 4.57 P A  	
Iron superoxide dismutase XP_001567555.1 21.7 6.62 P A  	
Paraflagellar rod protein 1D XP_001567017.1 69.3 5.21 A P 	 	
Isocitrate dehydrogenase XP_001568049.1 46.4 5.22 A P 	 	
Cytochrome c oxidase subunit IV XP_001563117.1 39.1 5.96 P P 	 	
Hypothetical protein XP_001566959.1 40.9 5.45 P P 	 	
Translation elongation factor 1 XP_001568778.1 23.0 4.32 A P 	 	
Heat shock protein 70 kDa XP_001566325.1 71.2 4.64 P P 	 	
Putative heat shock protein 70 XP_001566324.1 27.0 4.89 P P 	 	
Tryparedoxin peroxidase XP_001563558.1 22,6 6.51 A P 	 	
Hypothetical protein XP_001563170.1 13.2 5.46 P A 	 	
Proteasome activator protein pa26 XP_001568187.1 24.1 4.99 P A  	
Receptor for activated C kinase 1 XP_001566321.1 34.4 6.37 P A  	
a Name of the protein in L. braziliensis.
b Parasite stage in which the protein was identified. P, present; A, absent.
c Diagnosed by the serum class used in the recognition of the protein. CL, cutaneous leishmaniasis; ML, mucosal leishmaniasis.	 positive;, negative.
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FIG 3 Diagnostic performance of the recombinant proteins against a human serological panel. Serum samples derived from noninfected subjects living
in an area of leishmaniasis endemicity (n 30), as well as sera from cutaneous (n 23) or mucosal (n 20) leishmaniasis patients and sera from Chagas
disease patients (n 10), were used in the ELISAs. Reactivities against enolase (1.0 g per well), tryparedoxin peroxidase (0.5 g per well), hypothetical
protein (0.5 g per well), eukaryotic initiation factor 5a (0.05 g per well), -tubulin (0.01 g per well), and L. braziliensis SLA (2.0 g per well) were
determined. The mean optical density (OD) value was calculated by subtracting the mean blank OD from the OD mean for each sample by using the values
obtained in the ELISAs (A). The cutoff value for each diagnostic antigen was established based on their sensitivity and specificity values, which were obtained by
an ROC analysis (B).
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promastigote extracts, as well as amastigote-like-stage proteins,
were employed for the identification of the most antigenic pro-
teins of L. braziliensis. Amastigote-like forms were included, since
this parasite stage is present in themammal hosts a few hours after
infection and is responsible for the development of active disease
in the patients. In addition, the exclusion of the proteins by their
cross-reactivity with antibodies from sera of healthy subjects liv-
ing in areas of endemicity and those from Chagas disease patients
represent a refinement of the present proteomic analysis, allowing
the discarding of these antigenic proteins in order to be able to
diagnose false-positive patients.
The specificity of ELISAs using Leishmania antigenic prepara-
tions to diagnose leishmaniasis largely depends on the protein
formulation employed, although false-positive and false-negative
results have still been encountered in some studies (43–45). In the
present study, 20 proteins were identified as possible diagnostic
markers for TL. Most of them were expressed in both promastig-
ote and amastigote-like stages of the parasites. As a proof of con-
cept, five of them were selected to be evaluated as candidates in a
serological assay. Remarkably, none of them presented cross-re-
activity with the sera from Leishmania-noninfected subjects, val-
idating the strategy followed in this research project. The best
candidate antigen was the tryparedoxin peroxidase, which pre-
sented sensitivity and specificity values of 100% when sera from
CLorMLpatients were assayed. Tryparedoxin peroxidase belongs
to a family of proteins called peroxiredoxins, which are associated
with parasite virulence and have a high antigenicity during the
active disease. Previous studies have shown the antigenicity of
peroxiredoxins in dogs and humans infected by Leishmania infan-
tum or L. braziliensis (46, 47). Khosravi et al. showed that a real-
time PCR using the tryparedoxin peroxidase gene was specific for
CL diagnosis (48). In this case, the sensitivity and specificity values
encountered were 98.7 and 59.8%, respectively. The authors con-
cluded that this gene, when evaluated by a reverse transcription-
PCR (RT-PCR) technique, could be considered an effective
marker for the diagnosis of the disease. In another study, San-
tarém et al. showed that a combination between the tryparedoxin
peroxidase and K39 proteins was able to improve the VL serodi-
agnosis (49). However, to the best of our knowledge, an ELISA
employing tryparedoxin peroxidase has not been evaluated. Inter-
estingly, the present study showed that it is a viable alternative for
the serodiagnosis of TL.
Although enolase had been studied as a vaccine candidate
against experimental VL (50, 51), this antigen has not been eval-
uated as a diagnostic marker for TL, as also occurred for the eu-
karyotic initiation factor 5a and the hypothetical protein. All of
the proteins evaluated here presented sensitivity and specificity
values higher than those obtained using SLA from L. braziliensis as
an antigen.We concluded that all of them, alone or in a combined
form, could be included in future experiments looking for a more
sensitive and specific serodiagnosis test of TL. As an interesting
alternative, characterization of their immunodominant linear and
conformational antigenic determinants may be also a future line
of research for the development of such diagnostic tools. The use
of synthetic peptides containing the main epitopes of the proteins
is emerging as an interesting alternative to recombinant proteins
for the serodiagnosis of different diseases, since they are simpler
and cheaper to produce (52). Although this approach was not the
purpose of the present work, additional studies will certainly be
performed to predict the putative B cell epitopes of the new anti-
genically characterized proteins for their use in ELISAs. The final
objective is to obtain a precise, effective, easy to produce, and
cheap diagnostic antigen preparation to improve diagnostic per-
formance for the serodiagnosis of TL.
In conclusion, the present study has identified different anti-
genic L. braziliensis proteins that should be further analyzed. The
evaluation of larger human TL serological panels, as well as serum
samples obtained from patients developing related pathologies,
could be considered for the next steps. This is especially important
for those patients living in areas of endemicity who present skin
lesions similar to those found in TL patients, such as varicose
lesions or fungal skin lesions. We plan to validate not only the 5
selected candidates but also the rest of the 20 identified proteins.
In addition, and besides remission of the clinical lesions, the study
of the evolution of serology against these proteins during treat-
ment will be a further research pathway toward the development
of additional tools for the evaluation of recovery in patients after
treatment. In this context, data from the present study could be
taken as a proof of concept of the proposed antigens’ capacity for
TL serodiagnosis and may well serve as a reference for further
assays. However, these novel highly accurate recombinant pro-
teins and their use in ELISAs may be promptly applied to the
serodiagnosis used in TL due to their simplicity, ease of use, speed,
and reproducibility.
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TABLE 2 Diagnostic performance of tryparedoxin peroxidase, eukaryotic initiation factor 5a, enolase, -tubulin, and recombinant hypothetical
protein, as well as L. braziliensis SLA for serodiagnosis of TL
Antigen Cutoff valuea % sensitivity (95% CI) % specificity (95% CI) AUC (95% CI) % AC
Tryparedoxin peroxidase 0.374 100 (91.8–100) 100 (91.2–100) 1.0 (1.0–1.0) 100
Eukaryotic initiation factor 5a 0.100 100 (91.8–100) 92.5 (79.6–98.4) 1.0 (0.9–1.0) 96.4
Enolase 0.045 100 (91.8–100) 85.0 (70.2–94.3) 0.9 (0.9–1.0) 92.8
-Tubulin 0.081 100 (91.0–100) 82.5 (67.2–92.7) 0.9 (0.9–1.0) 91.6
Hypothetical protein 0.089 95.4 (84.2–99.4) 85.0 (70.2–94.3) 1.0 (0.9–1.0) 90.4
L. braziliensis SLA 0.743 65.1 (49.1–79.0) 57.5 (40.9–73.0) 0.6 (0.5–0.7) 61.4
a The cutoff values were obtained using the ROC curves, as well as the sensitivity, specificity, accuracy (AC) and area under the curve (AUC).
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